Sandra Le Quellec, MD, PhD

Global Clinical Program Leader, Clinical Development, Hematology
CSL Behring
King of Prussia, Philadelphia, Pennsylvania, United States

Sandra Le Quellec, MD, PhD, is currently Global Clinical Development Director for the therapeutic area of Haematology/Gene therapy at CSL Behring. She holds a PhD about AAV-based gene therapy for haemophilia B, and was formerly Associate Professor of Haematology at the University of Claude Bernard Lyon I, as well as a hospital practicioner physician taking care of patients with bleeding disorders.

Presentation(s):

• OC 02.3 - Etranacogene dezaparvovec hemophilia B gene therapy phase 2b trial final results: stable and durable FIX level expression over 5 years

  Saturday, June 22, 2024
  13:30 – 13:45 ICT